Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2)

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 221 participants.

Also called NCT06926842

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 221 participants (enrolled count) (from the registry)
Sponsor
  • Parexel Registry lists this organization as a collaborator
Registry
  • NCT NCT06926842
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT06926842. Randomized; double masking; primary purpose treatment. Start 2025-04-22 (actual); primary completion 2026-08-13 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2)
Condition
Overweight
Condition
Obesity
Intervention (Drug)
Petrelintide
Intervention (Other)
Placebo
Lead sponsor
Zealand Pharma (class: industry)
Collaborator
Parexel (class: industry)

Record details

Record id
cardio:ct-nct06926842
Content hash
bd4afb087f27c01898001cc54b8d018e848b538b721ac73b74753cfac32731af